Skip to main content
Clinical Trials/NCT02088528
NCT02088528UnknownNot Applicable

The Ghana Primary Tube Versus Trabeculectomy Study

Tema Christian Eye Center1 site in 1 country298 target enrollmentStarted: March 1, 2014Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
298
Locations
1
Primary Endpoint
Change in intraocular pressure

Study Overview

Brief Summary

Medical treatment of glaucoma in West Africa is often unsuccessful because of the cost of medications, disease severity and poor compliance. Surgical treatment is likely to be a more practical solution.

The purpose of this study is to compare the safety and efficacy of the Aurolab glaucoma drainage device against trabeculectomy with mitomycin-c in a prospective randomised surgical study.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 85 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Age 18 to 85 years, inclusive
  • •Open angle glaucoma. Including primary open angle glaucoma, pseudoexfoliative and pigmentary glaucoma
  • •Intraocular pressure 18 - 40 mmHg on maximal tolerated or maximal affordable medical therapy
  • •Informed consent given and consent form signed.

Exclusion Criteria

  • •Unwilling or unable to give consent, unwilling to accept randomisation, or unable to return for scheduled protocol visits
  • •Pregnant or nursing women
  • •No light perception vision
  • •Previous incisional intraocular surgery, other than uncomplicated clear corneal cataract surgery
  • •Previous ocular laser in study eye
  • •Iris neovascularisation or proliferative retinopathy
  • •Primary angle closure or primary angle closure glaucoma
  • •Iridocorneal endothelial syndrome or anterior segment dysgenesis
  • •Epithelial or fibrous downgrowth
  • •Chronic or recurrent uveitis
  • •Steroid-induced glaucoma
  • •Severe posterior blepharitis
  • •Unwilling to discontinue contact lens use after surgery
  • •Previous cyclodestructive procedure
  • •Glaucoma secondary to penetrating keratoplasty, trauma, retinal disease/surgery or neovascular disease
  • •Conjunctival scarring from prior ocular surgery, trauma or cicatrizing disease precluding a superior trabeculectomy
  • •Need for glaucoma surgery combined with other ocular procedures (i.e. cataract surgery, penetrating keratoplasty, or retinal surgery) or anticipated need for urgent additional ocular surgery

Arms & Interventions

Aurolab glaucoma drainage device

Active Comparator

Intervention: Aurolab glaucoma drainage device (Device)

Trabeculectomy with mitomycin-c

Active Comparator

Intervention: Trabeculectomy with mitomycin-c (Procedure)

Outcomes

Primary Outcomes

Change in intraocular pressure

Time Frame: 3 months, 6 months, 1 year, 18 months, 2 years, 2½ years, 3 years, 3½ years, 4 years, 4½ years, 5 years

Secondary Outcomes

  • Complication rates(1 day, 1 week, 1 month, 3 months, 6 months, 1 year, 18 months, 2 years, 2½ years, 3 years, 3½ years, 4 years, 4½ years, 5 years)
  • Visual acuity(1 day, 1 week, 1 month, 3 months, 6 months, 1 year, 18 months, 2 years, 2½ years, 3 years, 3½ years, 4 years, 4½ years, 5 years)
  • Visual field(6 months, 1 year, 2 years, 3 years, 4 years, 5 years)
  • Reoperation for glaucoma(1 day, 1 week, 1 month, 3 months, 6 months, 1 year, 18 months, 2 years, 2½ years, 3 years, 3½ years, 4 years, 4½ years, 5 years)
  • Supplemental medical therapy(1 day, 1 week, 1 month, 3 months, 6 months, 1 year, 18 months, 2 years, 2½ years, 3 years, 3½ years, 4 years, 4½ years, 5 years)
  • Quality of life(1 week, 1 month, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years)

Investigators

Sponsor
Tema Christian Eye Center
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Alex Spratt

Principal Investigator

Tema Christian Eye Center

Study Sites (1)

Loading locations...

Similar Trials